close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Home > About SYNVISC > Compare SYNVISC to Other Viscosupplements


Comparison of SYNVISC® to Other Viscosupplements

Used in over 2.2 million knees, SYNVISC is the leading viscosupplement in the United States—the only treatment of its kind that offers up to 6 months of pain relief with only 3 injections.

Review selected information from FDA-approved package inserts of SYNVISC and other viscosupplements—and see how the competition measures up.

  SYNVISC®
(hylan G-F 20) 		Hyalgan®
(sodium hyaluronate)1 		Supartz®
(sodium hyaluronate)2 		Orthovisc®
(high molecular weight hyaluronan)3 		Euflexxa™
(1% sodium hyaluronate)4
Molecular Weight (daltons) 6,000,000 500,000 - 730,000 620,000 - 1,7000,000 1,000,000 - 2,900,000 2,400,000 - 3,600,000
Directions for Use 3 injections: 1 week apart 3-5 injections: 1 week apart 3-5 injections: 1 week apart 3-4 injections: 1 week apart 3 injections: 1 week apart
Duration of Pain Relief with 3 Injections 26 weeks 60 days 90 days 22 weeks
(3 or 4 injections) 		12 weeks
Selected Local Adverse Events (all cause, % of patients) Knee pain and/or swelling: 7.2%* (2.2% of injections) Knee pain and swelling: 13%* Injection site reaction 5.7%†, Injections site pain: 4.2%* Injection site pain 2.5%*, Joint swelling: 0.7%*, Joint effusion: 0.4%*, Injection site edema: 0.9%* Multicenter studyT: Joint pain: 8.8%, Joint effusion: 0.6%, Joint swelling: 1.9%
Single center study*: Knee pain: 72%, Knee swelling: 4%
Number of Patients in Safety Population 551 patients 164 patients 619 patients 562 patients Multicenter studyT: 160 patients Single center study: 25 patients

*Placebo controlled trial.
†Includes application/injection site reaction, injection site inflammation, and purpura injections site.
T Head-to-head vs. SYNVISC.

Hyalgan is a registered trademark of Fidia S.P.A.
Supartz is a registered trademark of Seikugaku.
Orthovisc is a registered trademark of Anika Therapeutics, Inc.
Euflexxa is a trademark of Ferring Pharmaceuticals Inc.

Return to top



Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)